^
Association details:
| Biomarker: | CD74-ROS1 rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non–Small-Cell Lung Cancer
Published date:
02/15/2019
Excerpt:
A 77-year-old white man...He underwent RLL lobectomy, which confirmed T2aN1M0, stage IIA NSCLC….Comprehensive next-generation sequencing of tumor tissue obtained revealed a CD74-ROS1 rearrangement (Fig 1B). Crizotinib 250 mg orally twice daily was initiated...He remained disease free for 13 months until a follow-up CT scan of the chest showed relapse, with two RLL nodules.
DOI:
10.1200/PO.18.00267
